sarilumab
DRI13926
Phase 2 small_molecule active
Quick answer
sarilumab for Systemic Juvenile Idiopathic Arthritis (sJIA) is a Phase 2 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pharma Bristol-Myers Squibb
- Indication
- Systemic Juvenile Idiopathic Arthritis (sJIA)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active